References
- Arai H , YamamotoA, MatsuzawaY et al. Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000. J. Atheroscler. Thromb. 12(5) , 240–250 (2005).
- Lee E , RyanS, BirminghamB et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78(4) , 330–341 (2005).
- Tzeng TB , SchneckDW, BirminghamBK et al. Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Curr. Med. Res. Opin. 24(9) , 2575–2585 (2008).
- White CM . A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J. Clin. Pharmacol.42(9) , 963–970 (2002).
- Hu M , ToKK, MakVW, TomlinsonB. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin. Drug Metab. Toxicol.7(1) , 49–62 (2011).
- Romaine SP , BaileyKM, HallAS, BalmforthAJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J.10(1) , 1–11 (2009).
- Ho RH , TironaRG, LeakeBF et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130(6) , 1793–1806 (2006).
- Choi JH , LeeMG, ChoJY, LeeJE, KimKH, ParkK. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Ther.83(2) , 251–257 (2008).
- Pasanen MK , FredriksonH, NeuvonenPJ, NiemiM. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther.82(6) , 726–733 (2007).
- Zhang W , YuBN, HeYJ et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta 373(1–2) , 99–103 (2006).
- Keskitalo JE , ZolkO, FrommMF, KurkinenKJ, NeuvonenPJ, NiemiM. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther.86(2) , 197–203 (2009).
- Tomlinson B , HuM, LeeVW et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin. Pharmacol. Ther.87(5) , 558–562 (2010).
- Hu M , LuiSS, MakVW et al. Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenet. Genomics 20(10) , 634–637 (2010).
- Chasman DI , GiulianiniF, MacfadyenJ, BarrattBJ, NybergF, RidkerPM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ. Cardiovasc. Genet.5(2) , 257–264 (2012).
- Telbisz A , MullerM, Ozvegy-LaczkaC et al. Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochim. Biophys. Acta 1768(11) , 2698–2713 (2007).
- Rodrigues AC , HirataMH, HirataRD. Impact of cholesterol on ABC and SLC transporters expression and function and its role in disposition variability to lipid-lowering drugs. Pharmacogenomics10(6) , 1007–1016 (2009).
- Lee HK , HoCS, HuM, TomlinsonB, WongCK. Development and validation of a sensitive method for simultaneous determination of rosuvastatin and N-desmethyl rosuvastatin in human plasma using liquid chromatography/negative electrospray ionization/tandem mass spectrometry. Biomed. Chromatogr. doi:10.1002/bmc.2944 (2013) (Epub ahead of print).
- Hu M , MakVWL, ChuTTY, WayeMMY, TomlinsonB. Pharmacogenetics of HMG-CoA reductase inhibitors: optimizing the prevention of coronary heart disease. Curr. Pharmacogenomics Pers. Med.7(1) , 1–26 (2009).
- Zamber CP , LambaJK, YasudaK et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13(1) , 19–28 (2003).
- Morisaki K , RobeyRW, Ozvegy-LaczkaC et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother. Pharmacol. 56(2) , 161–172 (2005).
- Telbisz A , Ozvegy-LaczkaC, HegedusT, VaradiA, SarkadiB. Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein. Biochem. J.450(2) , 387–395 (2013).
- Merino G , van Herwaarden AE, Wagenaar E, Jonker JW, Schinkel AH. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol. Pharmacol.67(5) , 1765–1771 (2005).
- Martin PD , DaneAL, NwoseOM, SchneckDW, WarwickMJ. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J. Clin. Pharmacol.42(10) , 1116–1121 (2002).
- Konig J , CuiY, NiesAT, KepplerD. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol.278(1) , G156–G164 (2000).
- Iusuf D , van Esch A, Hobbs M et al. Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure. Mol. Pharmacol.83(5) , 919–929 (2013).
- Watanabe T , KusuharaH, MaedaK, ShitaraY, SugiyamaY. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther.328(2) , 652–662 (2009).
- Choi MK , ShinHJ, ChoiYL, DengJW, ShinJG, SongIS. Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica41(1) , 24–34 (2011).
- Niemi M , PasanenMK, NeuvonenPJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther.80(4) , 356–366 (2006).
- Kalliokoski A , NiemiM. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol.158(3) , 693–705 (2009).
- Weiss J , SauerA, DivacN et al. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm. Drug Dispos. 31(2–3) , 150–161 (2010).
- Sakaeda T , FujinoH, KomotoC et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm. Res. 23(3) , 506–512 (2006).
- Macwan JS , IonitaIA, AkhlaghiF. A simple assay for the simultaneous determination of rosuvastatin acid, rosuvastatin-5S-lactone, and N-desmethyl rosuvastatin in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Anal. Bioanal. Chem.402(3) , 1217–1227 (2012).